About KEYTRUDA in cervical cancer

KEYTRUDA® (pembrolizumab) in cervical cancer

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for:

	Persistent, recurrent, or metastatic cervical cancer
For use in	The treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1.1
Dosing schedule	The recommended dose is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.1
Duration of treatment	Treat until disease progression or unacceptable toxicity.1
Clinical trial	KEYNOTE-826 was a double-blind, phase III trial, for patients with persistent, recurrent, or metastatic cervical cancer assigned in a randomised 1:1 ratio, to receive pembrolizumab or placebo plus platinum-based chemotherapy and, per investigator discretion, bevacizumab.1 Click here to download the KEYNOTE-826 clinical data presentation Download

Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website